PhD, Duke University School of Medicine, 1982 - 1986
BA, Brandeis University, 1977 - 1981
Tarhini, A.A., Obermayer, A., Lee, S.J., LaFramboise, W.A., Hodi, F.S., Karunamurthy, A.D., Eljilany, I., Chen, D.T., Hwu, P., El Naqa, I.M., Streicher, H., Sondak, V.K., Storkus, W.J., Butterfield, L.H., Shaw, T.I., & Kirkwood, J.M. (2025). Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk Melanoma. Clin Cancer Res, of1-of10.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-24-3980.
Dong, B., Obermajer, N., Tsuji, T., Matsuzaki, J., Bonura, C.M., Sander, C., Withers, H., Long, M.D., Chavel, C., Olejniczak, S.H., Minderman, H., Kirkwood, J.M., Edwards, R.P., Storkus, W.J., Romero, P., & Kalinski, P. (2024). NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res, 12(10), 1421-1437.American Association for Cancer Research (AACR). doi: 10.1158/2326-6066.CIR-24-0061.
Karapetyan, L., Li, A., Vargas De Stefano, D., Abushukair, H.M., Al-Bzour, A.N., Knight, A., Layding, C., Wang, H., Xu, J., Yao, J., Song, X., Joy, M., Nguyen, J., Moran-Segura, C., Bruno, S., Sander, C., Messina, J., Mule, J.J., Storkus, W.J., & Kirkwood, J.M. (2024). Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas. J Immunother Cancer, 12(11), e009231.BMJ. doi: 10.1136/jitc-2024-009231.
Filderman, J.N., Luke, J.J., & Storkus, W.J. (2023). Platelet STING agonism and venous thrombosis: translational implications for improved disease outcomes. J Leukoc Biol, 114(3), 195-198.Oxford University Press (OUP). doi: 10.1093/jleuko/qiad073.
Karapetyan, L., AbuShukair, H.M., Li, A., Knight, A., Al Bzour, A.N., MacFawn, I.P., Thompson, Z.J., Chen, A., Yang, X., Dadey, R., Karunamurthy, A., De Stefano, D.V., Sander, C., Kunning, S.R., Najjar, Y.G., Davar, D., Luke, J.J., Gooding, W., Bruno, T.C., Kirkwood, J.M., & Storkus, W.J. (2023). Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes. Front Immunol, 14, 1171978.Frontiers. doi: 10.3389/fimmu.2023.1171978.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Supplementary Figure legends from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.22542652.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Supplementary Tables 1-2 from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.22542640.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Data from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.c.6550006.v1.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Supplementary Tables 1-2 from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.22542640.v1.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Supplementary Figures 1-6 from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.22542649.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Supplementary Figures 1-6 from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.22542649.v1.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Supplementary Figure legends from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.22542652.v1.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Data from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.c.6550006.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Supplementary Table legends from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.22542646.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2023). Supplementary Table legends from Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. doi: 10.1158/2326-6066.22542646.v1.
Bellavia, M.C., Nyiranshuti, L., Latoche, J.D., Ho, K.V., Fecek, R.J., Taylor, J.L., Day, K.E., Nigam, S., Pun, M., Gallazzi, F., Edinger, R.S., Storkus, W.J., Patel, R.B., & Anderson, C.J. (2022). PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma. Mol Imaging Biol, 24(3), 425-433.Springer Nature. doi: 10.1007/s11307-021-01666-1.
Filderman, J.N., & Storkus, W.J. (2022). Finding the right help in the tumor microenvironment. J Clin Invest, 132(12), e161052.American Society for Clinical Investigation. doi: 10.1172/JCI161052.
Gruenwald, V., & Storkus, W.J. (2022). Editorial: Immunotherapy in renal cell carcinoma. Front Oncol, 12, 945510.Frontiers. doi: 10.3389/fonc.2022.945510.
Karapetyan, L., Gooding, W., Li, A., Yang, X., Knight, A., Abushukair, H.M., Vargas De Stefano, D., Sander, C., Karunamurthy, A., Panelli, M., Storkus, W.J., Tarhini, A.A., & Kirkwood, J.M. (2022). Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma. Cancers (Basel), 14(20), 4973.MDPI. doi: 10.3390/cancers14204973.
Karapetyan, L., Yang, X., Knight, A.D., Huang, Z., Wang, H., Sander, C.A., Minnier, C.P., Wilson, M., Li, A., Karunamurthy, A., Storkus, W.J., & Kirkwood, J.M. (2022). Poorer survival outcomes in patients with multiple versus single primary melanoma. Cancer, 128(11), 2098-2106.Wiley. doi: 10.1002/cncr.34169.
Tarhini, A.A., Lee, S.J., Tan, A.C., El Naqa, I.M., Stephen Hodi, F., Butterfield, L.H., LaFramboise, W.A., Storkus, W.J., Karunamurthy, A.D., Conejo-Garcia, J.R., Hwu, P., Streicher, H., Sondak, V.K., & Kirkwood, J.M. (2022). Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer, 10(1), e004310.BMJ. doi: 10.1136/jitc-2021-004310.
Vats, K., Kruglov, O., Sahoo, B., Soman, V., Zhang, J., Shurin, G.V., Chandran, U.R., Skums, P., Shurin, M.R., Zelikovsky, A., Storkus, W.J., & Bunimovich, Y.L. (2022). Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses. Cancer Immunol Res, 10(9), 1141-1154.American Association for Cancer Research (AACR). doi: 10.1158/2326-6066.CIR-22-0110.
Amouzegar, A., Chelvanambi, M., Filderman, J.N., Storkus, W.J., & Luke, J.J. (2021). STING Agonists as Cancer Therapeutics. Cancers (Basel), 13(11), 2695.MDPI. doi: 10.3390/cancers13112695.
Chelvanambi, M., Fecek, R.J., Taylor, J.L., & Storkus, W.J. (2021). STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer, 9(2), e001906.BMJ. doi: 10.1136/jitc-2020-001906.
Close, D.A., Kirkwood, J.M., Fecek, R.J., Storkus, W.J., & Johnston, P.A. (2021). Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. SLAS Discov, 26(5), 712-729.Elsevier. doi: 10.1177/2472555220970917.
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W.J., & Guo, Z.S. (2021). Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer, 20(1), 171.Springer Nature. doi: 10.1186/s12943-021-01464-x.
Dasgupta, S., Ghosh, T., Dhar, J., Bhuniya, A., Nandi, P., Das, A., Saha, A., Das, J., Guha, I., Banerjee, S., Chakravarti, M., Dasgupta, P.S., Alam, N., Chakrabarti, J., Majumdar, S., Chakrabarti, P., Storkus, W.J., Baral, R., & Bose, A. (2021). RGS5-TGFβ-Smad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth. Cell Death Differ, 28(11), 3052-3076.Springer Nature. doi: 10.1038/s41418-021-00801-3.
Filderman, J.N., Appleman, M., Chelvanambi, M., Taylor, J.L., & Storkus, W.J. (2021). STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development. Front Immunol, 12, 690105.Frontiers. doi: 10.3389/fimmu.2021.690105.
Hao, X., Falo Iii, L.D., Chen, G., Zhang, J., Carey, C.D., Storkus, W.J., Falo, L.D., & You, Z. (2021). Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors. J Immunother Cancer, 9(1), e001179.BMJ. doi: 10.1136/jitc-2020-001179.
Lejeune, F.J., Storkus, W.J., & Riley, P.A. (2021). Thirty years of therapeutic innovation in melanoma research. Melanoma Res, 31(2), 105-107.Wolters Kluwer. doi: 10.1097/CMR.0000000000000723.
Pontrelli, P., Gigante, M., Spadaccino, F., Netti, G.S., Saldarelli, M., Balducci, L., Gigante, M., Battaglia, M., Storkus, W.J., Castellano, G., Stallone, G., Gesualdo, L., & Ranieri, E. (2021). CD40 Cross-Linking Induces Migration of Renal Tumor Cell through Nuclear Factor of Activated T Cells (NFAT) Activation. Int J Mol Sci, 22(16), 8871.MDPI. doi: 10.3390/ijms22168871.
Salem, D., Chelvanambi, M., Storkus, W.J., & Fecek, R.J. (2021). Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation. Front Immunol, 12, 629519.Frontiers. doi: 10.3389/fimmu.2021.629519.
Storkus, W.J., Maurer, D., Lin, Y., Ding, F., Bose, A., Lowe, D., Rose, A., DeMark, M., Karapetyan, L., Taylor, J.L., Chelvanambi, M., Fecek, R.J., Filderman, J.N., Looney, T.J., Miller, L., Linch, E., Lowman, G.M., Kalinski, P., Butterfield, L.H., Tarhini, A., Tawbi, H., & Kirkwood, J.M. (2021). Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer, 9(11), e003675.BMJ. doi: 10.1136/jitc-2021-003675.
Allen, A., Gau, D., Francoeur, P., Sturm, J., Wang, Y., Martin, R., Maranchie, J., Duensing, A., Kaczorowski, A., Duensing, S., Wu, L., Lotze, M.T., Koes, D., Storkus, W.J., & Roy, P. (2020). Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. J Biol Chem, 295(46), 15636-15649.Elsevier. doi: 10.1074/jbc.RA120.013963.
Chelvanambi, M., Weinstein, A.M., & Storkus, W.J. (2020). IL-36 Signaling in the Tumor Microenvironment. Adv Exp Med Biol, 1240, 95-110.Springer Nature. doi: 10.1007/978-3-030-38315-2_8.
Filderman, J.N., & Storkus, W.J. (2020). Neoepitopes as Difference Makers for General Cancer Vaccines?. Clin Cancer Res, 26(17), 4429-4431.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-20-2127.
Guha, I., Bhuniya, A., Shukla, D., Patidar, A., Nandi, P., Saha, A., Dasgupta, S., Ganguly, N., Ghosh, S., Nair, A., Majumdar, S., Saha, B., Storkus, W.J., Baral, R., & Bose, A. (2020). Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling. Front Immunol, 11, 898.Frontiers. doi: 10.3389/fimmu.2020.00898.
Guo, Z.S., Lotze, M.T., Zhu, Z., Storkus, W.J., & Song, X.T. (2020). Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines, 8(7), 204.MDPI. doi: 10.3390/biomedicines8070204.
Hwang, M.P., Fecek, R.J., Qin, T., Storkus, W.J., & Wang, Y. (2020). Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. J Control Release, 318, 270-278.Elsevier. doi: 10.1016/j.jconrel.2019.12.035.
Maurer, D.M., Adamik, J., Santos, P.M., Shi, J., Shurin, M.R., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2020). Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res, 8(12), 1554-1567.American Association for Cancer Research (AACR). doi: 10.1158/2326-6066.CIR-20-0274.
Razzo, B.M., Ludwig, N., Hong, C.S., Sharma, P., Fabian, K.P., Fecek, R.J., Storkus, W.J., & Whiteside, T.L. (2020). Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis, 41(5), 625-633.Oxford University Press (OUP). doi: 10.1093/carcin/bgz124.
Guo, Z.S., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., Liu, W., Storkus, W.J., He, Y., Liu, Z., & Bartlett, D.L. (2019). Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer, 7(1), 6.BMJ. doi: 10.1186/s40425-018-0495-7.
Ludwig, S., Hong, C.S., Razzo, B.M., Fabian, K.P.L., Chelvanambi, M., Lang, S., Storkus, W.J., & Whiteside, T.L. (2019). Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. Cancer Immunol Immunother, 68(7), 1133-1141.Springer Nature. doi: 10.1007/s00262-019-02348-2.
Russell, K.L., Gorgulho, C.M., Allen, A., Vakaki, M., Wang, Y., Facciabene, A., Lee, D., Roy, P., Buchser, W.J., Appleman, L.J., Maranchie, J., Storkus, W.J., & Lotze, M.T. (2019). Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. Cancer J, 25(3), 165-177.Wolters Kluwer. doi: 10.1097/PPO.0000000000000374.
Weinstein, A.M., Giraldo, N.A., Petitprez, F., Julie, C., Lacroix, L., Peschaud, F., Emile, J.F., Marisa, L., Fridman, W.H., Storkus, W.J., & Sautès-Fridman, C. (2019). Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunol Immunother, 68(1), 109-120.Springer Nature. doi: 10.1007/s00262-018-2259-0.
Choi, J., Beaino, W., Fecek, R.J., Fabian, K.P.L., Laymon, C.M., Kurland, B.F., Storkus, W.J., & Anderson, C.J. (2018). Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. J Nucl Med, 59(12), 1843-1849.Society of Nuclear Medicine. doi: 10.2967/jnumed.118.209510.
Fecek, R.J., Raveendran, S., Chelvanambi, M., & Storkus, W.J. (2018). Inhibition of HSPs for Enhanced Immunity. In Heat Shock Proteins in the Immune System. (pp. 157-180).Springer Nature. doi: 10.1007/978-3-319-69042-1_9.
Fabian, K.L., & Storkus, W.J. (2017). Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. Adv Exp Med Biol, 1036, 191-211.Springer Nature. doi: 10.1007/978-3-319-67577-0_13.
Fabian, K.P.L., Chi-Sabins, N., Taylor, J.L., Fecek, R., Weinstein, A., & Storkus, W.J. (2017). Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. Oncoimmunology, 6(3), e1290035.Taylor & Francis. doi: 10.1080/2162402X.2017.1290035.
Guo, Z.S., Liu, Z., Kowalsky, S., Feist, M., Kalinski, P., Lu, B., Storkus, W.J., & Bartlett, D.L. (2017). Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol, 8(MAY), 555.Frontiers. doi: 10.3389/fimmu.2017.00555.
Liu, Z., Hao, X., Zhang, Y., Zhang, J., Carey, C.D., Falo, L.D., Storkus, W.J., & You, Z. (2017). Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity. Oncoimmunology, 6(6), e1315487.Taylor & Francis. doi: 10.1080/2162402X.2017.1315487.
Vujanovic, L., Stahl, E.C., Pardee, A.D., Geller, D.A., Tsung, A., Watkins, S.C., Gibson, G.A., Storkus, W.J., & Butterfield, L.H. (2017). Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death. Cancer Immunol Res, 5(6), 493-502.American Association for Cancer Research (AACR). doi: 10.1158/2326-6066.CIR-16-0216.
Weinstein, A.M., Chen, L., Brzana, E.A., Patil, P.R., Taylor, J.L., Fabian, K.L., Wallace, C.T., Jones, S.D., Watkins, S.C., Lu, B., Stroncek, D.F., Denning, T.L., Fu, Y.X., Cohen, P.A., & Storkus, W.J. (2017). Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology, 6(6), e1322238.Taylor & Francis. doi: 10.1080/2162402X.2017.1322238.
Fecek, R.J., & Storkus, W.J. (2016). Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy, 8(10), 1205-1218.Taylor & Francis. doi: 10.2217/imt-2016-0071.
Ghosh, T., Barik, S., Bhuniya, A., Dhar, J., Dasgupta, S., Ghosh, S., Sarkar, M., Guha, I., Sarkar, K., Chakrabarti, P., Saha, B., Storkus, W.J., Baral, R., & Bose, A. (2016). Tumor-associated mesenchymal stem cells inhibit naïve T cell expansion by blocking cysteine export from dendritic cells. Int J Cancer, 139(9), 2068-2081.Wiley. doi: 10.1002/ijc.30265.
Gigante, M., Pontrelli, P., Herr, W.Gigante, M., D'Avenia, M., Zaza, G., Cavalcanti, E., Accetturo, M., Lucarelli, G., Carrieri, G., Battaglia, M., Storkus, W.J., Gesualdo, L., & Ranieri, E. (2016). miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. J Transl Med, 14(1), 84.Springer Nature. doi: 10.1186/s12967-016-0841-9.
Raïch-Regué, D., Fabian, K.P., Watson, A.R., Fecek, R.J., Storkus, W.J., & Thomson, A.W. (2016). Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. Oncoimmunology, 5(6), e1146841.Taylor & Francis. doi: 10.1080/2162402X.2016.1146841.
Tarhini, A.A., Tawbi, H., & Storkus, W.J. (2016). Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma. Melanoma Manag, 3(4), 251-254.Taylor & Francis. doi: 10.2217/mmt-2016-0016.
Weinstein, A.M., & Storkus, W.J. (2016). Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO. Front Immunol, 7(AUG), 301.Frontiers. doi: 10.3389/fimmu.2016.00301.
Lowe, D.B., Finke, J.H., Garcia, J.A., & Storkus, W.J. (2015). Vaccines in RCC: Clinical and Biological Relevance. 483-525.Springer Nature. doi: 10.1007/978-1-4939-1622-1_22.
Wang, X., Zhao, X., Feng, C., Weinstein, A., Xia, R., Wen, W., Lv, Q., Zuo, S., Tang, P., Yang, X., Chen, X., Wang, H., Zang, S., Stollings, L., Denning, T.L., Jiang, J., Fan, J., Zhang, G., Zhang, X., Zhu, Y., Storkus, W., & Lu, B. (2015). IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. Cancer Cell, 28(3), 296-306.Elsevier. doi: 10.1016/j.ccell.2015.07.014.
Weinstein, A.M., & Storkus, W.J. (2015). Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. Adv Cancer Res, 128, 197-233.Elsevier. doi: 10.1016/bs.acr.2015.04.003.
Zhang, Y., Chen, G., Liu, Z., Tian, S., Zhang, J., Carey, C.D., Murphy, K.M., Storkus, W.J., Falo, L.D., & You, Z. (2015). Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity. J Immunol, 194(12), 5937-5947.Oxford University Press (OUP). doi: 10.4049/jimmunol.1500089.
Lowe, D.B., Bose, A., Taylor, J.L., Tawbi, H., Lin, Y., Kirkwood, J.M., & Storkus, W.J. (2014). Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology, 3(1), e27589.Taylor & Francis. doi: 10.4161/onci.27589.
Lowe, D.B., Bose, A., Taylor, J.L., Tawbi, H., Lin, Y., Kirkwood, J.M., & Storkus, W.J. (2014). Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. ONCOIMMUNOLOGY, 3(2), e27589.Informa UK Limited. doi: 10.4161/onci.27589.
Lowe, D.B., Taylor, J.L., & Storkus, W.J. (2014). Monitoring antigen-specific T cell responses using real-time PCR. Methods Mol Biol, 1186, 65-74.Springer Nature. doi: 10.1007/978-1-4939-1158-5_5.
Vujanovic, L., Shi, J., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2014). Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8+ T-cell responses. Oncoimmunology, 3(8), e954501.Taylor & Francis. doi: 10.4161/21624011.2014.954501.
Wesa, A.K., Mandic, M., Taylor, J.L., Moschos, S., Kirkwood, J.M., Kwok, W.W., Finke, J.H., & Storkus, W.J. (2014). Circulating type-1 anti-tumor CD4+ T cells are preferentially pro-apoptotic in cancer patients. Frontiers in Oncology, 4 AUG. doi: 10.3389/fonc.2014.00225.
Wesa, A.K., Mandic, M., Taylor, J.L., Moschos, S., Kirkwood, J.M., Kwok, W.W., Finke, J.H., & Storkus, W.J. (2014). Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients. Front Oncol, 4, 266.Frontiers. doi: 10.3389/fonc.2014.00266.
Zhang, Y., Tian, S., Liu, Z., Zhang, J., Zhang, M., Bosenberg, M.W., Kedl, R.M., Waldmann, T.A., Storkus, W.J., Falo, L.D., & You, Z. (2014). Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. Oncoimmunology, 3(10), e959321.Taylor & Francis. doi: 10.4161/21624011.2014.959321.
Bose, A., Barik, S., Banerjee, S., Ghosh, T., Mallick, A., Bhattacharyya Majumdar, S., Goswami, K.K., Bhuniya, A., Banerjee, S., Baral, R., Storkus, W.J., Dasgupta, P.S., & Majumdar, S. (2013). Tumor-derived vascular pericytes anergize Th cells. J Immunol, 191(2), 971-981.Oxford University Press (OUP). doi: 10.4049/jimmunol.1300280.
Bose, A., Lowe, D.B., Rao, A., & Storkua, W.J. (2013). Combined vaccine + axitinib therapy yields superior antitumor efficacy in a murine melanoma model (vol 22, pg 236, 2012). MELANOMA RESEARCH, 23(2), 179.Wolters Kluwer. doi: 10.1097/CMR.0b013e32835857a2.
Chen, L., Fabian, K.L., Taylor, J.L., & Storkus, W.J. (2013). Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity. Front Immunol, 4, 388.Frontiers. doi: 10.3389/fimmu.2013.00388.
Chen, L., Taylor, J.L., Sabins, N.C., Lowe, D.B., Qu, Y., You, Z., & Storkus, W.J. (2013). Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther, 20(8), 469-477.Springer Nature. doi: 10.1038/cgt.2013.42.
Chi Sabins, N., Taylor, J.L., Fabian, K.P.L., Appleman, L.J., Maranchie, J.K., Stolz, D.B., & Storkus, W.J. (2013). DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. Mol Ther, 21(10), 1958-1968.Elsevier. doi: 10.1038/mt.2013.133.
Janelsins, B.M., Sumpter, T.L., Tkacheva, O.A., Rojas-Canales, D.M., Erdos, G., Mathers, A.R., Shufesky, W.J., Storkus, W.J., Falo, L.D., Morelli, A.E., & Larregina, A.T. (2013). Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood, 121(15), 2923-2933.American Society of Hematology. doi: 10.1182/blood-2012-07-446054.
Sabins, N.C., Taylor, J.L., Lowe, D.B., & Storkus, W.J. (2013). Molecular Immunotherapeutics and Vaccines for Renal Cell Carcinoma and Its Vasculature. In Molecular Vaccines. 1, (pp. 371-383).Springer Nature. doi: 10.1007/978-3-7091-1419-3_22.
Bose, A., Lowe, D.B., Rao, A., & Storkus, W.J. (2012). Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res, 22(3), 236-243.Wolters Kluwer. doi: 10.1097/CMR.0b013e3283538293.
Cohen, P.A., Ko, J.S., Storkus, W.J., Spencer, C.D., Bradley, J.M., Gorman, J.E., McCurry, D.B., Zorro-Manrique, S., Dominguez, A.L., Pathangey, L.B., Rayman, P.A., Rini, B.I., Gendler, S.J., & Finke, J.H. (2012). Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest, 41(6-7), 680-710.Taylor & Francis. doi: 10.3109/08820139.2012.703745.
Qu, Y., Chen, L., Lowe, D.B., Storkus, W.J., & Taylor, J.L. (2012). Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. Mol Ther, 20(3), 644-651.Elsevier. doi: 10.1038/mt.2011.283.
Rao, A., Lowe, D.B., & Storkus, W.J. (2012). Shock block for improved immunotherapy. Oncoimmunology, 1(8), 1427-1429.Taylor & Francis. doi: 10.4161/onci.21174.
Rao, A., Taylor, J.L., Chi-Sabins, N., Kawabe, M., Gooding, W.E., & Storkus, W.J. (2012). Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Res, 72(13), 3196-3206.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-12-0538.
Rao, A., Taylor, J.L., Chi-Sabins, N., Kawabe, M., Gooding, W.E., & Storkus, W.J. (2012). Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T Cells (vol 72, pg 3196, 2012). CANCER RESEARCH, 72(20), 5431.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-12-3249.
Zhao, X., Bose, A., Komita, H., Taylor, J.L., Chi, N., Lowe, D.B., Okada, H., Cao, Y., Mukhopadhyay, D., Cohen, P.A., & Storkus, W.J. (2012). Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol, 188(4), 1782-1788.Oxford University Press (OUP). doi: 10.4049/jimmunol.1101644.
Bose, A., Taylor, J.L., Alber, S., Watkins, S.C., Garcia, J.A., Rini, B.I., Ko, J.S., Cohen, P.A., Finke, J.H., & Storkus, W.J. (2011). Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer, 129(9), 2158-2170.Wiley. doi: 10.1002/ijc.25863.
Lowe, D.B., & Storkus, W.J. (2011). Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy, 3(10), 1265-1274.Taylor & Francis. doi: 10.2217/imt.11.113.
Qu, Y., Taylor, J.L., Bose, A., & Storkus, W.J. (2011). Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther, 18(9), 663-673.Springer Nature. doi: 10.1038/cgt.2011.37.
Zhao, X., Bose, A., Komita, H., Taylor, J.L., Kawabe, M., Chi, N., Spokas, L., Lowe, D.B., Goldbach, C., Alber, S., Watkins, S.C., Butterfield, L.H., Kalinski, P., Kirkwood, J.M., & Storkus, W.J. (2011). Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther, 19(4), 805-814.Elsevier. doi: 10.1038/mt.2010.295.
Cavalcanti, E., Gigante, M., Mancini, V., Battaglia, M., Ditonno, P., Capobianco, C., Cincione, R.I., Selvaggi, F.P., Herr, W., Storkus, W.J., Gesualdo, L., & Ranieri, E. (2010). JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients. J Biomed Biotechnol, 2010(1), 935764.Hindawi. doi: 10.1155/2010/935764.
Chi, N., Maranchie, J.K., Appleman, L.J., & Storkus, W.J. (2010). Update on vaccine development for renal cell cancer. Open Access J Urol, 2(1), 125-141. doi: 10.2147/rru.s7242.
Chi, N., Maranchie, J.K., Appleman, L.J., & Storkus, W.J. (2010). UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER. Open Access J Urol, 2010(2), 125-141.Taylor & Francis. doi: 10.2147/RRU.S7242.
Lipscomb, M.W., Taylor, J.L., Goldbach, C.J., Watkins, S.C., Wesa, A.K., & Storkus, W.J. (2010). DC expressing transgene Foxp3 are regulatory APC. Eur J Immunol, 40(2), 480-493.Wiley. doi: 10.1002/eji.200939667.
Pardee, A.D., McCurry, D., Alber, S., Hu, P., Epstein, A.L., & Storkus, W.J. (2010). A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res, 70(22), 9041-9052.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-10-1369.
Qu, Y., Chen, L., Pardee, A.D., Taylor, J.L., Wesa, A.K., & Storkus, W.J. (2010). Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. J Immunol, 185(5), 2895-2902.Oxford University Press (OUP). doi: 10.4049/jimmunol.1001294.
Schaubert, K.L., Price, D.A., Salkowitz, J.R., Sewell, A.K., Sidney, J., Asher, T.E., Blondelle, S.E., Adams, S., Marincola, F.M., Joseph, A., Sette, A., Douek, D.C., Ayyavoo, V., Storkus, W., Leung, M.Y., Ng, H.L., Yang, O.O., Goldstein, H., Wilson, D.B., & Kan-Mitchell, J. (2010). Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. Eur J Immunol, 40(7), 1950-1962.Wiley. doi: 10.1002/eji.200940079.
Finn, O.J., Binder, R.J., Brickner, A.G., Butterfield, L.H., Ferris, R.L., Kalinski, P., Okada, H., Storkus, W.J., Whiteside, T.L., & Zarour, H.M. (2009). Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines. In Tumor‐Associated Antigens. (pp. 23-43).Wiley. doi: 10.1002/9783527625970.ch2.
Gigante, M., Blasi, A., Loverre, A., Mancini, V., Battaglia, M., Selvaggi, F.P., Maiorano, E., Napoli, A., Castellano, G., Storkus, W.J., Gesualdo, L., & Ranieri, E. (2009). Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol, 46(5), 893-901.Elsevier. doi: 10.1016/j.molimm.2008.09.015.
Kawabe, M., Herrem, C.J., Finke, J.H., & Storkus, W.J. (2009). EphA2: A Novel Target in Renal Cell Carcinoma. In Renal Cell Carcinoma. (pp. 347-366).Springer Nature. doi: 10.1007/978-1-59745-332-5_20.
Kawabe, M., Mandic, M., Taylor, J.L., Vasquez, C.A., Wesa, A.K., Neckers, L.M., & Storkus, W.J. (2009). Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. Cancer Res, 69(17), 6995-7003.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-08-4511.
Komita, H., Zhao, X., Katakam, A.K., Kumar, P., Kawabe, M., Okada, H., Braughler, J.M., & Storkus, W.J. (2009). Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther, 16(12), 883-891.Springer Nature. doi: 10.1038/cgt.2009.33.
Lipscomb, M.W., Chen, L., Taylor, J.L., Goldbach, C., Watkins, S.C., Kalinski, P., Butterfield, L.H., Wesa, A.K., & Storkus, W.J. (2009). Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. J Immunol, 183(11), 7250-7258.Oxford University Press (OUP). doi: 10.4049/jimmunol.0901477.
Lipscomb, M.W., Storkus, W.J., & Wesa, A.K. (2009). Dendritic Cell Maturation Versus Polarization in Tumor Escape. In Dendritic Cells in Cancer. (pp. 257-268).Springer Nature. doi: 10.1007/978-0-387-88611-4_18.
Pardee, A.D., Wesa, A.K., & Storkus, W.J. (2009). Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy, 1(2), 249-264.Taylor & Francis. doi: 10.2217/1750743X.1.2.249.
Pardee, A.D., Wesa, A.K., & Storkus, W.J. (2009). Integrating costimulatory agonists to optimize immune-based cancer therapies. IMMUNOTHERAPY, 1(2), 249-264. doi: 10.2217/1750743X.1.2.249.
Sasaki, K., Pardee, A.D., Qu, Y., Zhao, X., Ueda, R., Kohanbash, G., Bailey, L.M., Okada, H., Muthuswamy, R., Kalinski, P., Basse, P.H., Falo, L.D., & Storkus, W.J. (2009). IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother, 32(8), 793-802.Wolters Kluwer. doi: 10.1097/CJI.0b013e3181acec1e.
Wieckowski, E.U., Visus, C., Szajnik, M., Szczepanski, M.J., Storkus, W.J., & Whiteside, T.L. (2009). Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol, 183(6), 3720-3730.Oxford University Press (OUP). doi: 10.4049/jimmunol.0900970.
Gigante, M., Mandic, M., Wesa, A.K., Cavalcanti, E., Dambrosio, M., Mancini, V., Battaglia, M., Gesualdo, L., Storkus, W.J., & Ranieri, E. (2008). Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother, 31(3), 254-262.Wolters Kluwer. doi: 10.1097/CJI.0b013e318167b023.
Komita, H., Zhao, X., Taylor, J.L., Sparvero, L.J., Amoscato, A.A., Alber, S., Watkins, S.C., Pardee, A.D., Wesa, A.K., & Storkus, W.J. (2008). CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Res, 68(19), 8076-8084.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-08-0387.
Moschos, S.J., Mandic, M., Kirkwood, J.M., Storkus, W.J., & Lotze, M.T. (2008). Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol, 127(2), 123-129.Elsevier. doi: 10.1016/j.clim.2008.02.011.
Moschos, S.J., Mandic, M., Kirkwood, J.M., Storkus, W.J., & Lotze, M.T. (2008). Focus on FOCIS: Interleukin 2 treatment associated autoimmunity. CLINICAL IMMUNOLOGY, 127(2), 123-129. doi: 10.1016/j.clim.2008.02.011.
Sasaki, K., Pardee, A.D., Okada, H., & Storkus, W.J. (2008). IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. Eur J Immunol, 38(10), 2865-2873.Wiley. doi: 10.1002/eji.200838334.
Sasaki, K., Zhao, X., Pardee, A.D., Ueda, R., Fujita, M., Sehra, S., Kaplan, M.H., Kane, L.P., Okada, H., & Storkus, W.J. (2008). Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol, 181(1), 104-108.Oxford University Press (OUP). doi: 10.4049/jimmunol.181.1.104.
Wesa, A.K., & Storkus, W.J. (2008). Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ, 15(1), 51-57.Springer Nature. doi: 10.1038/sj.cdd.4402243.
Wesa, A.K., Herrem, C.J., Mandic, M., Taylor, J.L., Vasquez, C., Kawabe, M., Tatsumi, T., Leibowitz, M.S., Finke, J.H., Bukowski, R.M., Bruckheimer, E., Kinch, M.S., & Storkus, W.J. (2008). Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. Journal of immunology (Baltimore, Md. : 1950), 181(11), 7721-7727.
Wesa, A.K., Herrem, C.J., Mandic, M., Taylor, J.L., Vasquez, C., Kawabe, M., Tatsumi, T., Leibowitz, M.S., Finke, J.H., Bukowski, R.M., Bruckheimer, E., Kinch, M.S., & Storkus, W.J. (2008). Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. J Immunol, 181(11), 7721-7727.Oxford University Press (OUP). doi: 10.4049/jimmunol.181.11.7721.
Atkins, M.B., Carbone, D., Coukos, G., Dhodapkar, M., Ernstoff, M.S., Finke, J., Gajewski, T.F., Gollob, J., Lotze, M.T., Storkus, W., & Weiner, L.M. (2007). Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother, 30(6), 577-590.Wolters Kluwer. doi: 10.1097/CJI.0b013e318064e7b2.
Berhanu, A., Huang, J., Watkins, S.C., Okada, H., & Storkus, W.J. (2007). Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. J Immunol, 178(6), 3400-3408.Oxford University Press (OUP). doi: 10.4049/jimmunol.178.6.3400.
Nakamura, Y., Watchmaker, P., Urban, J., Sheridan, B., Giermasz, A., Nishimura, F., Sasaki, K., Cumberland, R., Muthuswamy, R., Mailliard, R.B., Larregina, A.T., Falo, L.D., Gooding, W., Storkus, W.J., Okada, H., Hendricks, R.L., & Kalinski, P. (2007). Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res, 67(20), 10012-10018.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-07-1735.
Popescu, I., Macedo, C., Abu-Elmagd, K., Shapiro, R., Hua, Y., Thomson, A.W., Morelli, A.E., Storkus, W.J., & Metes, D. (2007). EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells. Am J Transplant, 7(5), 1215-1223.Elsevier. doi: 10.1111/j.1600-6143.2007.01740.x.
Ranieri, E., Gigante, M., Storkus, W.J., & Gesualdo, L. (2007). Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clin Exp Immunol, 147(3), 395-400.Oxford University Press (OUP). doi: 10.1111/j.1365-2249.2006.03305.x.
Sasaki, K., Zhu, X., Vasquez, C., Nishimura, F., Dusak, J.E., Huang, J., Fujita, M., Wesa, A., Potter, D.M., Walker, P.R., Storkus, W.J., & Okada, H. (2007). Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res, 67(13), 6451-6458.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-06-3280.
Storkus, W.J. (2007). Melanoma vaccines: in search of a clinical paradigm. Melanoma Res, 17(3), 137-138.Wolters Kluwer. doi: 10.1097/CMR.0b013e328153da7c.
Storkus, W.J., & Falo, L.D. (2007). A 'good death' for tumor immunology. Nat Med, 13(1), 28-30.Springer Nature. doi: 10.1038/nm0107-28.
Storkus, W.J., Herrem, C., Kawabe, M., Cohen, P.A., Bukowski, R.M., Finke, J.H., & Wesa, A.K. (2007). Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. Crit Rev Immunol, 27(5), 485-493.Begell House. doi: 10.1615/critrevimmunol.v27.i5.60.
Tatsumi, T., Takehara, T., Yamaguchi, S., Sasakawa, A., Miyagi, T., Jinushi, M., Sakamori, R., Kohga, K., Uemura, A., Ohkawa, K., Storkus, W.J., & Hayashi, N. (2007). Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther, 14(11), 863-871.Springer Nature. doi: 10.1038/sj.gt.3302941.
Vujanovic, L., Mandic, M., Olson, W.C., Kirkwood, J.M., & Storkus, W.J. (2007). A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. Clin Cancer Res, 13(22 Pt 1), 6796-6806.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-07-1909.
Wesa, A., Kalinski, P., Kirkwood, J.M., Tatsumi, T., & Storkus, W.J. (2007). Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother, 30(1), 75-82.Wolters Kluwer. doi: 10.1097/01.cji.0000211316.15278.6e.
Yamaguchi, S., Tatsumi, T., Takehara, T., Sakamori, R., Uemura, A., Mizushima, T., Ohkawa, K., Storkus, W.J., & Hayashi, N. (2007). Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer, 110(7), 1469-1477.Wiley. doi: 10.1002/cncr.22958.
Zhu, X., Nishimura, F., Sasaki, K., Fujita, M., Dusak, J.E., Eguchi, J., Fellows-Mayle, W., Storkus, W.J., Walker, P.R., Salazar, A.M., & Okada, H. (2007). Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med, 5(1), 10.Springer Nature. doi: 10.1186/1479-5876-5-10.
Berhanu, A., Huang, J., Alber, S.M., Watkins, S.C., & Storkus, W.J. (2006). Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. Cancer Res, 66(9), 4895-4903.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-05-2384.
Eguchi, J., Hatano, M., Nishimura, F., Zhu, X., Dusak, J.E., Sato, H., Pollack, I.F., Storkus, W.J., & Okada, H. (2006). Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res, 66(11), 5883-5891.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-06-0363.
Nishimura, F., Dusak, J.E., Eguchi, J., Zhu, X., Gambotto, A., Storkus, W.J., & Okada, H. (2006). Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res, 66(8), 4478-4487.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-05-3825.
Okano, F., Storkus, W.J., Chambers, W.H., Pollack, I.F., & Okada, H. (2006). Identification of a novel HLA-A* 0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain (vol 8, pg 2851, 2002). CLINICAL CANCER RESEARCH, 12(11), 3552. doi: 10.1158/1078-0432.CCR-12-11-COR.
Vujanovic, L., Ranieri, E., Gambotto, A., Olson, W.C., Kirkwood, J.M., & Storkus, W.J. (2006). IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther, 13(8), 798-805.Springer Nature. doi: 10.1038/sj.cgt.7700964.
Wankowicz-Kalinska, A., Mailliard, R.B., Olson, K., Graham, F., Edington, H., Kirkwood, J.M., Martinek, S., Das, P.K., & Storkus, W.J. (2006). Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Res, 16(2), 165-174.Wolters Kluwer. doi: 10.1097/01.cmr.0000198452.03957.73.
Eguchi, J., Kuwashima, N., Hatano, M., Nishimura, F., Dusak, J.E., Storkus, W.J., & Okada, H. (2005). IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J Immunol, 174(11), 7194-7201.Oxford University Press (OUP). doi: 10.4049/jimmunol.174.11.7194.
Hatano, M., Eguchi, J., Tatsumi, T., Kuwashima, N., Dusak, J.E., Kinch, M.S., Pollack, I.F., Hamilton, R.L., Storkus, W.J., & Okada, H. (2005). EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia, 7(8), 717-722.Elsevier. doi: 10.1593/neo.05277.
Herrem, C.J., Tatsumi, T., Olson, K.S., Shirai, K., Finke, J.H., Bukowski, R.M., Zhou, M., Richmond, A.L., Derweesh, I., Kinch, M.S., & Storkus, W.J. (2005). Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res, 11(1), 226-231.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.226.11.1.
Huang, J., Tatsumi, T., Pizzoferrato, E., Vujanovic, N., & Storkus, W.J. (2005). Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Res, 65(18), 8461-8470.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-05-0654.
Kalinski, P., Giermasz, A., Nakamura, Y., Basse, P., Storkus, W.J., Kirkwood, J.M., & Mailliard, R.B. (2005). Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol, 42(4), 535-539.Elsevier. doi: 10.1016/j.molimm.2004.07.038.
Kalinski, P., Mailliard, R.B., Geskin, L., Giermasz, A., Nakamura, Y., Storkus, W.J., Lotze, M.T., Bartlett, D.L., Kirkwood, J.M., & Falo, L.D. (2005). Polarized DC1-based therapeutic cancer vaccines. JOURNAL OF IMMUNOTHERAPY, 28(6), 656.Wolters Kluwer. doi: 10.1097/01.cji.0000191090.97275.78.
Kuwashima, N., Nishimura, F., Eguchi, J., Sato, H., Hatano, M., Tsugawa, T., Sakaida, T., Dusak, J.E., Fellows-Mayle, W.K., Papworth, G.D., Watkins, S.C., Gambotto, A., Pollack, I.F., Storkus, W.J., & Okada, H. (2005). Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol, 175(4), 2730-2740.Oxford University Press (OUP). doi: 10.4049/jimmunol.175.4.2730.
Macedo, C., Donnenberg, A., Popescu, I., Reyes, J., Abu-Elmagd, K., Shapiro, R., Zeevi, A., Fung, J.J., Storkus, W.J., & Metes, D. (2005). EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. Transpl Immunol, 14(2), 109-116.Elsevier. doi: 10.1016/j.trim.2005.02.001.
Macedo, C., Popescu, I., Abu-Elmagd, K., Reyes, J., Shapiro, R., Zeevi, A., Berghaus, J.M., Wang, L.F., Lu, L., Thomson, A.W., Storkus, W.J., Fung, J.J., & Metes, D. (2005). Augmentation of type-1 polarizing ability of monocyte-derived dendritic cells from chronically immunosuppressed organ-transplant recipients. Transplantation, 79(4), 451-459.Wolters Kluwer. doi: 10.1097/01.tp.0000146589.49756.7f.
Muller-Berghaus, J., Olson, W.C., Moulton, R.A., Knapp, W.T., Schadendorf, D., & Storkus, W.J. (2005). IL-12 production by human monocyte-derived dendritic cells: looking at the single cell. J Immunother, 28(4), 306-313.Wolters Kluwer. doi: 10.1097/01.cji.0000163594.74533.10.
Sandel, M.H., Speetjens, F.M., Menon, A.G., Albertsson, P.A., Basse, P.H., Hokland, M., Nagelkerke, J.F., Tollenaar, R.A.E.M., van de Velde, C.J.H., & Kuppen, P.J.K. (2005). Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol, 42(4), 541-546.Elsevier. doi: 10.1016/j.molimm.2004.07.039.
Warrino, D.E., Olson, W.C., Scarrow, M.I., D'Ambrosio-Brennan, L.J., Guido, R.S., Da Silva, D.M., Kast, W.M., & Storkus, W.J. (2005). Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol, 66(7), 762-772.Elsevier. doi: 10.1016/j.humimm.2005.04.006.
Hatano, M., Kuwashima, N., Tatsumi, T., Dusak, J.E., Nishimura, F., Reilly, K.M., Storkus, W.J., & Okada, H. (2004). Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med, 2(1), 40.Springer Nature. doi: 10.1186/1479-5876-2-40.
Mailliard, R.B., Wankowicz-Kalinska, A., Cai, Q., Wesa, A., Hilkens, C.M., Kapsenberg, M.L., Kirkwood, J.M., Storkus, W.J., & Kalinski, P. (2004). alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res, 64(17), 5934-5937.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-04-1261.
Okada, H., Tsugawa, T., Sato, H., Kuwashima, N., Gambotto, A., Okada, K., Dusak, J.E., Fellows-Mayle, W.K., Papworth, G.D., Watkins, S.C., Chambers, W.H., Potter, D.M., Storkus, W.J., & Pollack, I.F. (2004). Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res, 64(16), 5830-5838.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-04-0130.
Pizzoferrato, E., Liu, Y., Gambotto, A., Armstrong, M.J., Stang, M.T., Gooding, W.E., Alber, S.M., Shand, S.H., Watkins, S.C., Storkus, W.J., & Yim, J.H. (2004). Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res, 64(22), 8381-8388.American Association for Cancer Research (AACR). doi: 10.1158/0008-5472.CAN-04-2223.
Rayman, P., Wesa, A.K., Richmond, A.L., Das, T., Biswas, K., Raval, G., Storkus, W.J., Tannenbaum, C., Novick, A., Bukowski, R., & Finke, J. (2004). Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res, 10(18 Pt 2), 6360S-6366S.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-050011.
Warrino, D.E., Olson, W.C., Knapp, W.T., Scarrow, M.I., D'Ambrosio-Brennan, L.J., Guido, R.S., Edwards, R.P., Kast, W.M., & Storkus, W.J. (2004). Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res, 10(10), 3301-3308.American Association for Cancer Research (AACR). doi: 10.1158/1078-0432.CCR-03-0498.
Hoffman, T.K., MullerBerghaus, J., Ferris, R.L., Johnson, J.T., Storkus, W.J., & Whiteside, T.L. (2003). Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck (vol 8, pg 1787, 2002). CLINICAL CANCER RESEARCH, 9(1), 441.
Kalinski, P., Cai, Q., Mailliard, R.B., Kalinska, A., Storkus, W.J., & Kirkwood, J.M. (2003). Type-1 polarized DC obtained in serum-free conditions are powerful inducers of anti-melanoma responses. FASEB JOURNAL, 17(7), C331.
KALINSKI, P., STORKUS, W., THOMSON, A., & LOTZE, M. (2003). Interleukin-12 Family [IL-12, 23, 12RA and 27]. In The Cytokine Handbook. (pp. 383-408).Elsevier. doi: 10.1016/b978-012689663-3/50020-x.
Mailliard, R.B., Son, Y.I., Redlinger, R., Coates, P.T., Giermasz, A., Morel, P.A., Storkus, W.J., & Kalinski, P. (2003). Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol, 171(5), 2366-2373.Oxford University Press (OUP). doi: 10.4049/jimmunol.171.5.2366.
Nakahara, N., Pollack, I.F., Storkus, W.J., Wakabayashi, T., Yoshida, J., & Okada, H. (2003). Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther, 10(7), 549-558.Springer Nature. doi: 10.1038/sj.cgt.7700598.
Popescu, I., Macedo, C., Zeevi, A., Nellis, J., Patterson, K.R., Logar, A., Rowe, D., Reyes, J., Rao, A.S., Storkus, W.J., Fung, J.J., & Metes, D. (2003). Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. Am J Transplant, 3(11), 1369-1377.Elsevier. doi: 10.1046/j.1600-6135.2003.00252.x.
ROBBINS, P., STORKUS, W., & GAMBOTTO, A. (2003). Cytokine gene transfer. In The Cytokine Handbook. (pp. 1335-1348).Elsevier. doi: 10.1016/b978-012689663-3/50063-6.
Tatsumi, T., Herrem, C.J., Olson, W.C., Finke, J.H., Bukowski, R.M., Kinch, M.S., Ranieri, E., & Storkus, W.J. (2003). Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res, 63(15), 4481-4489.
Tatsumi, T., Huang, J., Gooding, W.E., Gambotto, A., Robbins, P.D., Vujanovic, N.L., Alber, S.M., Watkins, S.C., Okada, H., & Storkus, W.J. (2003). Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res, 63(19), 6378-6386.
Tatsumi, T., Kierstead, L.S., Ranieri, E., Gesualdo, L., Schena, F.P., Finke, J.H., Bukowski, R.M., Brusic, V., Sidney, J., Sette, A., Logan, T.F., Kasamon, Y.L., Slingluff, C.L., Kirkwood, J.M., & Storkus, W.J. (2003). MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res, 9(3), 947-954.
Wankowicz-Kalinska, A., Le Poole, C., van den Wijngaard, R., Storkus, W.J., & Das, P.K. (2003). Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?. Pigment Cell Res, 16(3), 254-260.Wiley. doi: 10.1034/j.1600-0749.2003.00038.x.
Wańkowicz-Kalińska, A., van den Wijngaard, R.M.J.G.J., Tigges, B.J., Westerhof, W., Ogg, G.S., Cerundolo, V., Storkus, W.J., & Das, P.K. (2003). Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest, 83(5), 683-695.Elsevier. doi: 10.1097/01.lab.0000069521.42488.1b.
Asai, T., Storkus, W.J., Mueller-Berghaus, J., Knapp, W., DeLeo, A.B., Chikamatsu, K., & Whiteside, T.L. (2002). In vitro generated cytolytic T lymphocytes reactive against head and neckcancer recognize multiple epitopes presented by HLA-A2, including peptidesderived from the p53 and MDM-2 proteins. Cancer Immunity, 5, 1-17.
Asai, T., Storkus, W.J., Mueller-Berghaus, J., Knapp, W., DeLeo, A.B., Chikamatsu, K., & Whiteside, T.L. (2002). In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immun, 2, 3.
Bennouna, J., Hildesheim, A., Chikamatsu, K., Gooding, W., Storkus, W.J., & Whiteside, T.L. (2002). Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. J Immunol Methods, 261(1-2), 145-156.Elsevier. doi: 10.1016/s0022-1759(01)00566-x.
Björck, P., Lie, W.R., Woulfe, S.L., Klein, B.K., Olson, W., & Storkus, W.J. (2002). Progenipoietin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model. Int J Cancer, 100(5), 586-591.Wiley. doi: 10.1002/ijc.10529.
Bykovskaia, S.N., Shurin, G.V., Graner, S., Bunker, M.L., Olson, W., Thomas, R., Shurin, M.R., Marks, S., Storkus, W.J., & Shogan, J. (2002). Differentiation of immunostimulatory stem-cell- and monocyte-derived dendritic cells involves maturation of intracellular compartments responsible for antigen presentation and secretion. Stem Cells, 20(5), 380-393.Oxford University Press (OUP). doi: 10.1634/stemcells.20-5-380.
Hoffmann, T.K., Müller-Berghaus, J., Ferris, R.L., Johnson, J.T., Storkus, W.J., & Whiteside, T.L. (2002). Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res, 8(6), 1787-1793.
Janjic, B.M., Lu, G., Pimenov, A., Whiteside, T.L., Storkus, W.J., & Vujanovic, N.L. (2002). Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol, 168(4), 1823-1830.Oxford University Press (OUP). doi: 10.4049/jimmunol.168.4.1823.
Keilholz, U., Weber, J., Finke, J.H., Gabrilovich, D.I., Kast, W.M., Disis, M.L., Kirkwood, J.M., Scheibenbogen, C., Schlom, J., Maino, V.C., Lyerly, H.K., Lee, P.P., Storkus, W., Marincola, F., Worobec, A., & Atkins, M.B. (2002). Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother, 25(2), 97-138.Wolters Kluwer. doi: 10.1097/00002371-200203000-00001.
Lokshin, A.E., Kalinski, P., Sassi, R.R., Mailliard, R.B., Müller-Berghaus, J., Storkus, W.J., Peng, X., Marrangoni, A.M., Edwards, R.P., & Gorelik, E. (2002). Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. Int Immunol, 14(9), 1027-1037.Oxford University Press (OUP). doi: 10.1093/intimm/dxf073.
Lotze, M.T., Mailliard, R.B., Tanaka, F., Tahara, H., Storkus, W.J., & Kalinksi, P. (2002). DC-activating function of cytokines [IL-12, IL-18], T cells and NK cells in the development of antitumor responses. CLINICAL IMMUNOLOGY, 103(3), S103-S104.
Lu, G., Janjic, B.M., Janjic, J., Whiteside, T.L., Storkus, W.J., & Vujanovic, N.L. (2002). Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol, 168(4), 1831-1839.Oxford University Press (OUP). doi: 10.4049/jimmunol.168.4.1831.
Mailliard, R.B., Egawa, S., Cai, Q., Kalinska, A., Bykovskaya, S.N., Lotze, M.T., Kapsenberg, M.L., Storkus, W.J., & Kalinski, P. (2002). Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med, 195(4), 473-483.Rockefeller University Press. doi: 10.1084/jem.20011662.
Okano, F., Storkus, W.J., Chambers, W.H., Pollack, I.F., & Okada, H. (2002). Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res, 8(9), 2851-2855.
Tatsumi, T., & Storkus, W.J. (2002). Dendritic cell-based vaccines and therapies for cancer. Expert Opin Biol Ther, 2(8), 919-928.Taylor & Francis. doi: 10.1517/14712598.2.8.919.
Tatsumi, T., Gambotto, A., Robbins, P.D., & Storkus, W.J. (2002). Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Res, 62(20), 5853-5858.
Tatsumi, T., Kierstead, L.S., Ranieri, E., Gesualdo, L., Schena, F.P., Finke, J.H., Bukowski, R.M., Mueller-Berghaus, J., Kirkwood, J.M., Kwok, W.W., & Storkus, W.J. (2002). Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med, 196(5), 619-628.Rockefeller University Press. doi: 10.1084/jem.20012142.
Hoffmann, T.K., Meidenbauer, N., Müller-Berghaus, J., Storkus, W.J., & Whiteside, T.L. (2001). Proinflammatory Cytokines and CD40 Ligand Enhance Cross-Presentation and Cross-Priming Capability of Human Dendritic Cells Internalizing Apoptotic Cancer Cells. J Immunother (1991), 24(2), 162-171.Wolters Kluwer. doi: 10.1097/00002371-200103000-00011.
Hoffmann, T.K., Meidenbauer, N., Müller-Berghaus, J., Storkus, W.J., & Whiteside, T.L. (2001). Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother, 24(2), 162-171. doi: 10.1097/00002371-200103000-00011.
Kierstead, L.S., Ranieri, E., Olson, W., Brusic, V., Sidney, J., Sette, A., Kasamon, Y.L., Slingluff, C.L., Kirkwood, J.M., & Storkus, W.J. (2001). gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer, 85(11), 1738-1745.Springer Nature. doi: 10.1054/bjoc.2001.2160.
Larregina, A.T., Watkins, S.C., Erdos, G., Spencer, L.A., Storkus, W.J., Beer Stolz, D., & Falo, L.D. (2001). Direct transfection and activation of human cutaneous dendritic cells. Gene Ther, 8(8), 608-617.Springer Nature. doi: 10.1038/sj.gt.3301404.
Le, P.T., Adams, K.L., Zaya, N., Mathews, H.L., Storkus, W.J., & Ellis, T.M. (2001). Human thymic epithelial cells inhibit IL-15- and IL-2-driven differentiation of NK cells from the early human thymic progenitors. J Immunol, 166(4), 2194-2201.Oxford University Press (OUP). doi: 10.4049/jimmunol.166.4.2194.
Mailliard, R.B., Egawa, S., Cai, Q., Kalinska, A., Lotze, M.T., Kapsenberg, M.L., Storkus, W.J., & Kalinski, P. (2001). Polarized dendritic cells mediate CDS help for CD4+ T cells:: Helper function of CD8+ T cells in the development of Th1 responses. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 117(4), 1022.
Metes, D., Storkus, W.J., Zeevi, A., Watkins, S., Patterson, K., Nellis, J., Logar, A., Fung, J.J., & Rao, A.S. (2001). Use of autologous dendritic cells loaded with apoptotic LCL for ex vivo generation of specific CTL from the PBMC of EBV(-) individuals. Transplant Proc, 33(1-2), 441.Elsevier. doi: 10.1016/s0041-1345(00)02084-4.
Asai, T., Storkus, W.J., & Whiteside, T.L. (2000). Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol, 7(2), 145-154.American Society for Microbiology. doi: 10.1128/CDLI.7.2.145-154.2000.
Dong, X., An, B., Salvucci Kierstead, L., Storkus, W.J., Amoscato, A.A., & Salter, R.D. (2000). Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cells. J Immunol, 164(1), 129-135.Oxford University Press (OUP). doi: 10.4049/jimmunol.164.1.129.
Herr, W., Ranieri, E., Olson, W., Zarour, H., Gesualdo, L., & Storkus, W.J. (2000). Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood, 96(5), 1857-1864.American Society of Hematology. doi: 10.1182/blood.V96.5.1857.h8001857_1857_1864.
Lotze, M.T., Shurin, M., Esche, C., Tahara, H., Storkus, W., Kirkwood, J.M., Whiteside, T.L., Elder, E.M., Okada, H., & Robbins, P. (2000). Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am, 6 Suppl 1(SUPPL. 1), S61-S66.
Metes, D., Storkus, W., Zeevi, A., Patterson, K., Logar, A., Rowe, D., Nalesnik, M.A., Fung, J.J., & Rao, A.S. (2000). Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. Transplantation, 70(10), 1507-1515.Wolters Kluwer. doi: 10.1097/00007890-200011270-00019.
Ranieri, E., Kierstead, L.S., Zarour, H., Kirkwood, J.M., Lotze, M.T., Whiteside, T., & Storkus, W.J. (2000). Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest, 29(2), 121-125.Taylor & Francis. doi: 10.3109/08820130009062294.
Storkus, W.J., & Zarour, H.M. (2000). Melanoma antigens recognized by CD8+ and CD4+ T cells. Forum (Genova), 10(3), 256-270.
Tüting, T., Austyn, J., Storkus, W.J., & Falo, L.D. (2000). The immunology of DNA vaccines. Methods Mol Med, 29, 37-64.Springer Nature. doi: 10.1385/1-59259-688-6:37.
Zarour, H.M., Kirkwood, J.M., Kierstead, L.S., Herr, W., Brusic, V., Slingluff, C.L., Sidney, J., Sette, A., & Storkus, W.J. (2000). Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A, 97(1), 400-405.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.97.1.400.
Zarour, H.M., Storkus, W.J., Brusic, V., Williams, E., & Kirkwood, J.M. (2000). NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res, 60(17), 4946-4952.
Chikamatsu, K., Nakano, K., Storkus, W.J., Appella, E., Lotze, M.T., Whiteside, T.L., & DeLeo, A.B. (1999). Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res, 5(6), 1281-1288.
Dong, X., Storkus, W.J., & Salter, R.D. (1999). Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. J Immunol, 163(10), 5427-5434.Oxford University Press (OUP). doi: 10.4049/jimmunol.163.10.5427.
Herr, W., Ranieri, E., Gambotto, A., Kierstead, L.S., Amoscato, A.A., Gesualdo, L., & Storkus, W.J. (1999). Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci U S A, 96(21), 12033-12038.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.96.21.12033.
Ranieri, E., Herr, W., Gambotto, A., Olson, W., Rowe, D., Robbins, P.D., Kierstead, L.S., Watkins, S.C., Gesualdo, L., & Storkus, W.J. (1999). Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol, 73(12), 10416-10425.American Society for Microbiology. doi: 10.1128/JVI.73.12.10416-10425.1999.
Tüting, T., Gambotto, A., DeLeo, A., Lotze, M.T., Robbins, P.D., & Storkus, W.J. (1999). Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther, 6(1), 73-80.Springer Nature. doi: 10.1038/sj.cgt.7700020.
Tüting, T., Gambotto, A., Robbins, P.D., Storkus, W.J., & DeLeo, A.B. (1999). Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther, 6(4), 629-636.Springer Nature. doi: 10.1038/sj.gt.3300859.
Wilson, C.C., Olson, W.C., Tuting, T., Rinaldo, C.R., Lotze, M.T., & Storkus, W.J. (1999). HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. J Immunol, 162(5), 3070-3078.Oxford University Press (OUP). doi: 10.4049/jimmunol.162.5.3070.
Falo, L.D., & Storkus, W.J. (1998). Giving DNA vaccines a helping hand. Nat Med, 4(11), 1239-1240.Springer Nature. doi: 10.1038/3217.
Myers, J.N., Mank-Seymour, A., Zitvogel, L., Storkus, W., Clarke, M., Johnson, C.S., Tahara, H., & Lotze, M.T. (1998). Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope, 108(2), 261-268.Wiley. doi: 10.1097/00005537-199802000-00019.
Tjandrawan, T., Martin, D.M., Maeurer, M.J., Castelli, C., Lotze, M.T., & Storkus, W.J. (1998). Third keystone symposium on cellular immunology and the immunotherapy of cancer antigen processing and presentation autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. Journal of Immunotherapy, 21(2), 157-149. doi: 10.1097/00002371-199803000-00009.
Tjandrawan, T., Martin, D.M., Maeurer, M.J., Castelli, C., Lotze, M.T., & Storkus, W.J. (1998). Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother, 21(2), 149-157.Wolters Kluwer. doi: 10.1097/00002371-199803000-00009.
Tüting, T., Storkus, W.J., & Falo, L.D. (1998). DNA immunization targeting the skin: molecular control of adaptive immunity. J Invest Dermatol, 111(2), 183-188.Elsevier. doi: 10.1046/j.1523-1747.1998.00261.x.
Tüting, T., Wilson, C.C., Martin, D.M., Baar, J., DeLeo, A., Lotze, M.T., & Storkus, W.J. (1998). DNA vaccines targeting dendritic cells for the immunotherapy of cancer. Adv Exp Med Biol, 451, 295-304.Springer Nature. doi: 10.1007/978-1-4615-5357-1_46.
Tüting, T., Wilson, C.C., Martin, D.M., Kasamon, Y.L., Rowles, J., Ma, D.I., Slingluff, C.L., Wagner, S.N., van der Bruggen, P., Baar, J., Lotze, M.T., & Storkus, W.J. (1998). Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol, 160(3), 1139-1147.Oxford University Press (OUP). doi: 10.4049/jimmunol.160.3.1139.
Lotze, M.T., Hellerstedt, B., Stolinski, L., Tueting, T., Wilson, C., Kinzler, D., Vu, H., Rubin, J.T., Storkus, W., Tahara, H., Elder, E., & Whiteside, T. (1997). The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am, 3 Suppl 1(SUPPL. 1), S109-S114.
Lotze, M.T., Shurin, M., Davis, I., Amoscato, A., & Storkus, W.J. (1997). Dendritic cell based therapy of cancer. Adv Exp Med Biol, 417, 551-569.Springer Nature. doi: 10.1007/978-1-4757-9966-8_91.
Maeurer, M.J., Walter, W., Martin, D., Zitvogel, L., Elder, E., Storkus, W., & Lotze, M.T. (1997). Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand J Immunol, 45(2), 182-192.Wiley. doi: 10.1046/j.1365-3083.1997.d01-384.x.
Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Garcia-Prats, M.D., DeLeo, A.B., & Lotze, M.T. (1997). Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells, 15(2), 94-103.Oxford University Press (OUP). doi: 10.1002/stem.150094.
Shurin, M.R., Pandharipande, P.P., Zorina, T.D., Haluszczak, C., Subbotin, V.M., Hunter, O., Brumfield, A., Storkus, W.J., Maraskovsky, E., & Lotze, M.T. (1997). FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol, 179(2), 174-184.Elsevier. doi: 10.1006/cimm.1997.1152.
Tüting, T., DeLeo, A.B., Lotze, M.T., & Storkus, W.J. (1997). Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol, 27(10), 2702-2707.Wiley. doi: 10.1002/eji.1830271033.
Tüting, T., Gambotto, A., Baar, J., Davis, I.D., Storkus, W.J., Zavodny, P.J., Narula, S., Tahara, H., Robbins, P.D., & Lotze, M.T. (1997). Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther, 4(10), 1053-1060.Springer Nature. doi: 10.1038/sj.gt.3300509.
Tüting, T., Storkus, W.J., & Lotze, M.T. (1997). Gene-based strategies for the immunotherapy of cancer. J Mol Med (Berl), 75(7), 478-491.Springer Nature. doi: 10.1007/s001090050133.
Amoscato, A.A., Storkus, W.J., & Lotze, M.T. (1996). Secretion of a 93 kda gelatinase by human peripheral blood dendritic cells. FASEB JOURNAL, 10(6), 2787.
Bernhard, H., Maeurer, M.J., Jäger, E., Wölfel, T., Schneider, J., Karbach, J., Seliger, B., Huber, C., Storkus, W.S., Lotze, M.T., Meyer zum Büschenfelde, K.H., & Knuth, A. (1996). Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma. Scand J Immunol, 44(3), 285-292.Wiley. doi: 10.1046/j.1365-3083.1996.d01-304.x.
Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., & Falo, L.D. (1996). Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med, 183(1), 283-287.Rockefeller University Press. doi: 10.1084/jem.183.1.283.
Galon, J., Gauchat, J.F., Mazières, N., Spagnoli, R., Storkus, W., Lötze, M., Bonnefoy, J.Y., Fridman, W.H., & Sautès, C. (1996). Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol, 157(3), 1184-1192.Oxford University Press (OUP). doi: 10.4049/jimmunol.157.3.1184.
Lotze, M.T., Zitvogel, L., Campbell, R., Robbins, P.D., Elder, E., Haluszczak, C., Martin, D., Whiteside, T.L., Storkus, W.J., & Tahara, H. (1996). Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci, 795(1), 440-454.Wiley. doi: 10.1111/j.1749-6632.1996.tb52715.x.
Maeurer, M.J., Chan, H.W., Karbach, J., Salter, R.D., Knuth, A., Lotze, M.T., & Storkus, W.J. (1996). Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. Eur J Immunol, 26(11), 2613-2623.Wiley. doi: 10.1002/eji.1830261112.
Maeurer, M.J., Gollin, S.M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W.J., & Lotze, M.T. (1996). Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest, 98(7), 1633-1641.American Society for Clinical Investigation. doi: 10.1172/JCI118958.
Maeurer, M.J., Gollin, S.M., Storkus, W.J., Swaney, W., Karbach, J., Martin, D., Castelli, C., Salter, R., Knuth, A., & Lotze, M.T. (1996). Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res, 2(4), 641-652.
Maeurer, M.J., Martin, D., Elder, E., Storkus, W.J., & Lotze, M.T. (1996). Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Clin Cancer Res, 2(1), 87-95.
Maeurer, M.J., Martin, D., Walter, W., Liu, K., Zitvogel, L., Halusczcak, K., Rabinowich, H., Duquesnoy, R., Storkus, W., & Lotze, M.T. (1996). Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med, 183(4), 1681-1696.Rockefeller University Press. doi: 10.1084/jem.183.4.1681.
Maeurer, M.J., Storkus, W.J., Kirkwood, J.M., & Lotze, M.T. (1996). New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res, 6(1), 11-24.Wolters Kluwer. doi: 10.1097/00008390-199602000-00003.
Mayordomo, J.I., Loftus, D.J., Sakamoto, H., De Cesare, C.M., Appasamy, P.M., Lotze, M.T., Storkus, W.J., Appella, E., & DeLeo, A.B. (1996). Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med, 183(4), 1357-1365.Rockefeller University Press. doi: 10.1084/jem.183.4.1357.
Mazzocchi, A., Storkus, W.J., Traversari, C., Tarsini, P., Maeurer, M.J., Rivoltini, L., Vegetti, C., Belli, F., Anichini, A., Parmiani, G., & Castelli, C. (1996). Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J Immunol, 157(7), 3030-3038.Oxford University Press (OUP). doi: 10.4049/jimmunol.157.7.3030.
Storkus, W.J., Wei, M., Cresswell, P., & Dawson, J.R. (1996). Class I-like CD1A-C do not protect target cells from NK-mediated cytolysis. Cell Immunol, 167(1), 154-156.Elsevier. doi: 10.1006/cimm.1996.0020.
Storkus, W.J., Zitvogel, L., Tueting, T., Couderc, B.C., Baar, J., Rowles, J., Tjandrawan, T., Robbins, P.D., Wilson, C.C., Ma, D.I., Edington, H.D., & Lotze, M.T. (1996). Genetically-modified dendritic cells serve as effective adjuvants in promoting anti-tumor immunity in vitro and in vivo. FASEB JOURNAL, 10(6), 2551.
Tahara, H., Zitvogel, L., Storkus, W.J., Robbins, P.D., & Lotze, M.T. (1996). Murine models of cancer cytokine gene therapy using interleukin-12. Ann N Y Acad Sci, 795(1), 275-283.Wiley. doi: 10.1111/j.1749-6632.1996.tb52677.x.
Zitvogel, L., Couderc, B., Mayordomo, J.I., Robbins, P.D., Lotze, M.T., & Storkus, W.J. (1996). IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci, 795(1), 284-293.Wiley. doi: 10.1111/j.1749-6632.1996.tb52678.x.
Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., & Storkus, W.J. (1996). Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med, 183(1), 87-97.Rockefeller University Press. doi: 10.1084/jem.183.1.87.
Zitvogel, L., Robbins, P.D., Storkus, W.J., Clarke, M.R., Maeurer, M.J., Campbell, R.L., Davis, C.G., Tahara, H., Schreiber, R.D., & Lotze, M.T. (1996). Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol, 26(6), 1335-1341.Wiley. doi: 10.1002/eji.1830260624.
Castelli, C., Storkus, W.J., Maeurer, M.J., Martin, D.M., Huang, E.C., Pramanik, B.N., Nagabhushan, T.L., Parmiani, G., & Lotze, M.T. (1995). Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med, 181(1), 363-368.Rockefeller University Press. doi: 10.1084/jem.181.1.363.
Frassanito, M.A., Mayordomo, J.I., DeLeo, R.M., Storkus, W.J., Lotze, M.T., & DeLeo, A.B. (1995). Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte. Cancer Res, 55(1), 124-128.
Maeurer, M., Zitvogel, L., Elder, E., Storkus, W.J., & Lotze, M.T. (1995). Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun, 14(4), 188-197.
Maeurer, M.J., Hurd, S., Martin, D.M., Storkus, W.J., & Lotze, M.T. (1995). Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage. Cancer J Sci Am, 1(2), 162-170.
Maeurer, M.J., Martin, D.M., Castelli, C., Elder, E., Leder, G., Storkus, W.J., & Lotze, M.T. (1995). Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother, 41(2), 111-121.Springer Nature. doi: 10.1007/BF01527407.
Maeurer, M.J., Martin, D.M., Storkus, W.J., & Lotze, M.T. (1995). TCR usage in CTLs recognizing melanoma/melanocyte antigens. Immunol Today, 16(12), 603-604.Elsevier. doi: 10.1016/0167-5699(95)80084-0.
Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., Ildstad, S.T., Kast, W.M., & Deleo, A.B. (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med, 1(12), 1297-1302.Springer Nature. doi: 10.1038/nm1295-1297.
Tahara, H., Lotze, M.T., Robbins, P.D., Storkus, W.J., & Zitvogel, L. (1995). IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther, 6(12), 1607-1624.Mary Ann Liebert. doi: 10.1089/hum.1995.6.12-1607.
Tahara, H., Zitvogel, L., Storkus, W.J., Zeh, H.J., McKinney, T.G., Schreiber, R.D., Gubler, U., Robbins, P.D., & Lotze, M.T. (1995). Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol, 154(12), 6466-6474.Oxford University Press (OUP). doi: 10.4049/jimmunol.154.12.6466.
Zitvogel, L., Tahara, H., Robbins, P.D., Storkus, W.J., Clarke, M.R., Nalesnik, M.A., & Lotze, M.T. (1995). Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol, 155(3), 1393-1403.Oxford University Press (OUP). doi: 10.4049/jimmunol.155.3.1393.
Itoh, T., Storkus, W.J., Gorelik, E., & Lotze, M.T. (1994). Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. J Immunol, 153(3), 1202-1215.Oxford University Press (OUP). doi: 10.4049/jimmunol.153.3.1202.
Leder, G.H., Storkus, W.J., Stuber, G., Modrow, S., & Lotze, M.T. (1994). Erratum: (Langenbecks Archiv fur Chirurgie, Forumband 1994). Langenbecks Archiv fur Chirurgie, 379(4), 254.
Nastala, C.L., Edington, H.D., McKinney, T.G., Tahara, H., Nalesnik, M.A., Brunda, M.J., Gately, M.K., Wolf, S.F., Schreiber, R.D., & Storkus, W.J. (1994). Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol, 153(4), 1697-1706.Oxford University Press (OUP). doi: 10.4049/jimmunol.153.4.1697.
Stuber, G., Leder, G.H., Storkus, W.T., Lotze, M.T., Modrow, S., Székely, L., Wolf, H., Klein, E., Kärre, K., & Klein, G. (1994). Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol, 24(3), 765-768.Wiley. doi: 10.1002/eji.1830240341.
Tahara, H., Zeh, H.J., Storkus, W.J., Pappo, I., Watkins, S.C., Gubler, U., Wolf, S.F., Robbins, P.D., & Lotze, M.T. (1994). Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res, 54(1), 182-189.
Zeh, H.J., Leder, G.H., Lotze, M.T., Salter, R.D., Tector, M., Stuber, G., Modrow, S., & Storkus, W.J. (1994). Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol, 39(2), 79-86.Elsevier. doi: 10.1016/0198-8859(94)90105-8.
Zitvogel, L., Tahara, H., Cai, Q., Storkus, W.J., Muller, G., Wolf, S.F., Gately, M., Robbins, P.D., & Lotze, M.T. (1994). Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther, 5(12), 1493-1506.Mary Ann Liebert. doi: 10.1089/hum.1994.5.12-1493.
Storkus, W.J., Zeh, H.J., Maeurer, M.J., Salter, R.D., & Lotze, M.T. (1993). Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol, 151(7), 3719-3727.Oxford University Press (OUP). doi: 10.4049/jimmunol.151.7.3719.
Storkus, W.J., Zeh, H.J., Salter, R.D., & Lotze, M.T. (1993). Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol, 14(2), 94-103.Wolters Kluwer. doi: 10.1097/00002371-199308000-00003.
Zeh, H.J., Hurd, S., Storkus, W.J., & Lotze, M.T. (1993). Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother Emphasis Tumor Immunol, 14(2), 155-161.Wolters Kluwer. doi: 10.1097/00002371-199308000-00012.
Storkus, W.J., Salter, R.D., Cresswell, P., & Dawson, J.R. (1992). Peptide-induced modulation of target cell sensitivity to natural killing. J Immunol, 149(4), 1185-1190.Oxford University Press (OUP). doi: 10.4049/jimmunol.149.4.1185.
Storkus, W.J., & Dawson, J.R. (1991). Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. Crit Rev Immunol, 10(5), 393-416.
Storkus, W.J., Salter, R.D., Alexander, J., Ward, F.E., Ruiz, R.E., Cresswell, P., & Dawson, J.R. (1991). Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2. Proc Natl Acad Sci U S A, 88(14), 5989-5992.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.88.14.5989.
Miller, M.F., Mitchell, T.G., Storkus, W.J., & Dawson, J.R. (1990). Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect Immun, 58(3), 639-645.American Society for Microbiology. doi: 10.1128/iai.58.3.639-645.1990.
Storkus, W.J., Alexander, J., Payne, J.A., Cresswell, P., & Dawson, J.R. (1989). The α1/α2 domains of class I HLA molecules confer resistance to natural killing. Journal of Immunology, 143(11), 3853-3857.
Storkus, W.J., Alexander, J., Payne, J.A., Cresswell, P., & Dawson, J.R. (1989). The alpha 1/alpha 2 domains of class I HLA molecules confer resistance to natural killing. J Immunol, 143(11), 3853-3857.Oxford University Press (OUP). doi: 10.4049/jimmunol.143.11.3853.
Storkus, W.J., Alexander, J., Payne, J.A., Dawson, J.R., & Cresswell, P. (1989). Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A, 86(7), 2361-2364.Proceedings of the National Academy of Sciences. doi: 10.1073/pnas.86.7.2361.
Storkus, W.J., Howell, D.N., Salter, R.D., Dawson, J.R., & Cresswell, P. (1987). NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol, 138(6), 1657-1659.Oxford University Press (OUP). doi: 10.4049/jimmunol.138.6.1657.
Storkus, W.J., & Dawson, J.R. (1986). B cell sensitivity to natural killing: correlation with target cell stage of differentiation and state of activation. J Immunol, 136(5), 1542-1547.Oxford University Press (OUP). doi: 10.4049/jimmunol.136.5.1542.
Storkus, W.J., & Dawson, J.R. (1986). Oxygen-reactive metabolites are not detected at the effector-target interface during natural killing. J Leukoc Biol, 39(5), 547-557.Oxford University Press (OUP). doi: 10.1002/jlb.39.5.547.
Storkus, W.J., Balber, A.E., & Dawson, J.R. (1986). Quantitation and sorting of vitally stained natural killer cell-target cell conjugates by dual beam flow cytometry. Cytometry, 7(2), 163-170.Wiley. doi: 10.1002/cyto.990070207.
Karapetyan, L., Gooding, W., Yang, X., Knight, A., Li, A., Sander, C., Panelli, M., Storkus, W.J., Tarhini, A.A., & Kirkwood, J.M. (2022). Sentinel lymph node gene expression signature predicts survival outcome in cutaneous melanoma. In CANCER RESEARCH, 82(12).
Karapetyan, L., Gooding, W., Yang, X., Knight, A., Li, A., Sander, C., Panelli, M., Storkus, W.J., Tarhini, A.A., & Kirkwood, J.M. (2022). Sentinel lymph node gene expression signature predicts survival outcome in cutaneous melanoma. In CANCER RESEARCH, 82(12).
Falo, L.D.I.I.I., Hao, X., Chen, G., Carey, C.D., Liu, Z., Bartlett, D., Storkus, W.J., Falo, L.D.J., & You, Z. (2021). PD1 Blockade of Tumor-primed CD4 T Cells Instigates Protective Immunity Against Tumor Rechallenge. In JOURNAL OF IMMUNOLOGY, 206.
Filderman, J., Chelvanambi, M., & Storkus, W.J. (2021). STING agonism combined with arginase and PTGES/COX2 inhibitors for improved anti -tumor immunotherapeutic benefit. In JOURNAL OF IMMUNOLOGY, 206.
Karapetyan, L., Yang, X., Wang, H., Sander, C., Karunamurthy, A., Kirkwood, J.M., & Storkus, W.J. (2021). Serum multiplex analysis of tertiary lymphoid structure-associated chemokines/cytokines in melanoma patients. In CANCER RESEARCH, 81(13).
Hwang, M.P., Fecek, R.J., Qin, T.M., Storkus, W., & Wang, Y. (2019). Heparin-based il-12 complex coacervate inhibits B16F10 melanoma tumor progression. In Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium, 40, (p. 342).
Razzo, B.M., Hong, C.S., Fabian, K.P., Ludwig, N., Sharma, P., Storkus, W.J., & Whiteside, T.L. (2018). Head and neck cancer-derived exosomes facilitate carcinogenesis in the murine 4NQO chemically induced oropharyngeal cancer. In CANCER RESEARCH, 78(13), (p. 1748).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM2018-1748.
Weinstein, A.M., Chen, L., Giraldo, N., Petitprez, F., Lacroix, L., Brzana, E.A., Fridman, W.H., Sautes-Fridman, C., & Storkus, W.J. (2018). IL-36γ promotes a local immune response via the formation of tertiary lymphoid structures in colorectal carcinoma. In JOURNAL OF IMMUNOLOGY, 200(1).
Weinstein, A.M., Giraldo, N.A., Julie, C., Lacroix, L., Petitprez, F., Emile, J.F., Fridman, W.H., Storkus, W.J., & Sautes-Fridman, C. (2017). Expression pattern and prognostic value of IL-36g in colorectal cancer. In JOURNAL FOR IMMUNOTHERAPY OF CANCER, 5.
Raveendran, S., Fecek, R., Carey, C.D., & Storkus, W.J. (2016). Combination immunotherapy targeting HSP90 DNA -repair client proteins overexpressed in chemotherapy -resistant melanoma. In CANCER RESEARCH, 76.
Weinstein, A.M., Chen, L., & Storkus, W.J. (2016). Modulation of tumor vasculature promotes tertiary lymphoid organogenesis. In JOURNAL OF IMMUNOLOGY, 196.
Lowe, D.B., Bose, A., & Storkus, W.J. (2012). Combined vaccine plus axitinib therapy yields superior anti-tumor efficacy in a murine melanoma model. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 132, (p. S104).
Rao, A., Kawabe, M., & Storkus, W.J. (2012). Immunostimulatory effects of HSP90 inhibition: Insights from combinational immunotherapies targeting EphA2. In CANCER RESEARCH, 72(8_Supplement), (p. 4399).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM2012-4399.
Sabins, N.C., Bose, A., & Storkus, W.J. (2012). Tumor Pericytes: A Novel Target for Immunotherapy in Renal Cell Carcinoma. In MOLECULAR THERAPY, 20, (p. S130).
Taylor, J.L., Qu, Y., Chen, L., Lowe, D.B., & Storkus, W.J. (2012). Combined Tbet and IL-12 gene therapy elicits and recruits superior anti-tumor immunity in vivo. In CANCER RESEARCH, 72(8_Supplement), (p. 1537).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM2012-1537.
Vujanovic, L., Kirkwood, J.M., Storkus, W.J., & Butterfield, L.H. (2012). Induction of MAGE-A6-Specific CD8+T-cell Responses Using MAGE-A6 and Mycoplasma Penetrans HF-2 Permease-derived Peptides. In JOURNAL OF IMMUNOTHERAPY, 35(9), (p. 746).
Rao, P., Kawabe, M., & Storkus, W.J. (2011). Integration of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) in combinational immunotherapy targeting tumor antigen EphA2. In CANCER RESEARCH, 71(8_Supplement), (p. 1805).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM2011-1805.
Pardee, A.D., Epstein, A.L., & Storkus, W.J. (2010). A novel OX40 agonist licenses systemic anti-tumor immunity to overcome local immune suppression induced by well-established tumors. In CANCER RESEARCH, 70(8_Supplement), (p. 2938).American Association for Cancer Research (AACR). doi: 10.1158/1538-7445.AM10-2938.
Komita, H., Amoscato, A.A., Alber, S.M., Wesa, A.K., & Storkus, W.J. (2008). Hemoglobin-beta as a Tumor-rejection Antigen Allowing Immune Targeting of the Tumor-associated Stroma. In JOURNAL OF IMMUNOTHERAPY, 31(9), (p. 965).
Pardee, A.D., Epstein, A.L., Alber, S., Watkins, S.C., Wesa, A.K., & Storkus, W.J. (2008). Late-stage Tumors are Enriched in T Cells Bearing a GITRHI/OX40+ Phenotype and are Effectively Treated With GITR and OX40 Agonists. In JOURNAL OF IMMUNOTHERAPY, 31(9), (p. 933).
Scholnicoff, E.T., Wesa, A., & Storkus, W.J. (2008). Indoleamine 2,3-dioxygenase Expression in Renal Cell Carcinoma. In JOURNAL OF IMMUNOTHERAPY, 31(9), (p. 967).
Komita, H., & Storkus, W.J. (2007). Dendritic cells engineered to secrete interleukin-12 P70 when delivered into tumors results in the crosspriming of an expanded anti-tumor CD8+ T cell repertoire and therapeutic benefit. In JOURNAL OF IMMUNOTHERAPY, 30(8), (p. 896).
Komita, H., Mandic, M., Kawabe, M., & Storkus, W.J. (2007). RTK-based vaccines elicit specific CD8+T cell responses in HLA-A2 transgenic mice. In JOURNAL OF IMMUNOLOGY, 178.
Mandic, M., Kawabe, M., Vasquez, A.C., & Storkus, W.J. (2007). Conditional triggering of EphA2 epitope presentation results in the enhanced tumor cell recognition by specific CTL. In JOURNAL OF IMMUNOLOGY, 178.
Wesa, A.K., Kirkwood, J.M., Kwok, W.W., & Storkus, W.J. (2007). Apoptosis of circulating tumor-antigen specific TH1 CD4+ T cells from melanoma patients. In JOURNAL OF IMMUNOTHERAPY, 30(8), (p. 866).
Kalinski, P., Mailliard, R., Geskin, L., Giermasz, A., Nakamura, Y., Watchmaker, P., Muthuswamy, R., Storkus, W.J., Bartlett, D., Edington, H., Falo, L.D.J., & Kirkwood, J.M. (2006). Polarized DCs as therapeutic cancer vaccines. In CANCER RESEARCH, 66(8).
Kuwashima, N., Nishimura, F., Eguchi, J., Sato, H., Hatano, M., Tsugawa, T., Sakaida, T., Dusak, J.E., Fellows-Mayle, W.K., Papworth, G.D., Watkins, S.C., Gambotto, A., Pollack, I.F., Storkus, W.J., Okada, H., & Yanaga, K. (2006). Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: Dependence on apoptotic pathways. In JOURNAL OF GENE MEDICINE, 8(12), (p. 1449).
Sasaki, K., Zhu, X., Fujita, M., Nishimura, F., Dusak, J.E., Storkus, W.J., & Okada, H. (2006). Preferential expression of VLA-4 on Tc1 cells plays a critical role in trafficking into central nervous system tumors. In NEURO-ONCOLOGY, 8(4), (p. 430).
Storkus, W.J., Watkins, S.C., Huang, J., & Berhanu, A. (2006). Treatment-enhanced CD4+Foxp3+GITRHi T cells limit the effectiveness of cytokine-based immunotherapy. In JOURNAL OF IMMUNOLOGY, 176, (p. S276).
Wesa, A., Mandic, M., Kirkwood, J.M., Kwok, W., & Storkus, W.J. (2006). Circulating tumor-antigen specific CD4 T cells in melanoma patients have a pro-apoptotic phenotype. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 126, (p. 123).
Yamaguchi, S., Tatsumi, T., Takehara, T., Sasakawa, A., Fujita, Y., Sakamori, R., Uemura, A., Kohga, K., Ohkawa, K., Hiramatsu, N., Kanto, T., Storkus, W.J., & Hayashi, N. (2006). Efficacy of immunotherapy with the receptor tyrosine kinase EPHA2 derived peptides-pulsed dendritic cells in mouse liver tumor. In HEPATOLOGY, 44(4), (p. 524A).
Huang, J., & Storkus, W.J. (2005). Sensitization of tumor cells to dendritic cell-mediated apoptosis by nitric oxide via a Fas-dependent pathway. In FASEB JOURNAL, 19(4), (p. A413).
Wesa, A., Kalinski, P., Kirkwood, J.M., & Storkus, W.J. (2005). Rescuing anti-melanoma CD4+ responses with type-1 polarized dendritic cells: Essential roles of extended IL-12 family members. In JOURNAL OF IMMUNOTHERAPY, 28(6), (p. 661).Wolters Kluwer. doi: 10.1097/01.cji.0000191105.81066.35.
Finke, J.H., Tannenbaum, C., Storkus, W., Rayman, P., Das, T., Biswas, K., Richmond, A., Moon, C., Thornton, M., Gill, I., Novick, A., & Bukowski, R. (2004). Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis. In Urologe A, 43 Suppl 3(Suppl 3), (pp. S131-S132).Springer Nature.Germany. doi: 10.1007/s00120-004-0600-z.
Hatano, M., Tatsumi, T., Kuwashima, N., Dusak, J.E., Pollack, I.F., Storkus, W.J., & Okada, H. (2004). As a glioma/angiogenesis-associated antigen: A target for novel glioma immunotherapy strategies. In NEURO-ONCOLOGY, 6(4), (p. 342).
Lotze, M.T., Tahara, H., Storkus, W.J., Whiteside, T.L., Hall, T., Kinzler, D., & Zeh, H.J. (2004). Ten year experience and followup of effective gene therapy in patients with cancer. In ANNALS OF SURGICAL ONCOLOGY, 11(2), (pp. S78-S79).Springer Nature. doi: 10.1007/BF02524058.
Wesa, A., Kalinski, P., John, M.K., & Storkus, W.J. (2004). Restoration of TH1 CD4+ T cell responses to melanoma antigens with type-1 polarized dendritic cells. In JOURNAL OF IMMUNOTHERAPY, 27(6), (p. S34).Wolters Kluwer. doi: 10.1097/00002371-200411000-00124.
Zarour, H.M., Land, S., Sander, C., Mascari, R., Storkus, W.J., Shipe-Spotloe, J., Stover, L., Herberman, R.B., Agarwala, S.S., & Kirkwood, J.M. (2004). Phase I-II vaccine trial with MHC class II and MHC class I epitopes from melan-A/MART-1 for patients with metastatic melanoma. In JOURNAL OF CLINICAL ONCOLOGY, 22(14), (p. 169S).
Herrem, C.J., Tatsumi, T., Olson, W., Finke, J.H., Bukowski, R.M., Kinch, M.S., & Storkus, W.J. (2003). CD8+ and CD4+ T cell-mediated immunity against novel EphA2-derived epitopes in patients with renal cell carcinoma. In FASEB JOURNAL, 17(7), (p. C333).
Ranieri, E., Cellie, M., Pontrelli, P., Di Natale, C., Blasi, A., Capobianco, C., Mancini, V., Ditonno, P., Battaglia, M., Selvaggi, F.P., Storkus, W.J., Grandaliano, G., Schena, F.P., & Gesualdo, L. (2003). CD40/CD40L interaction activates JNK and NF-kB in renal cell carcinoma (RCC). In JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 14, (p. 554A).
Ranieri, E., Tatsumi, T., Kierstead, L.S., Finke, J.H., Bukowski, R.M., Brusic, V., Sidney, J., Sette, A., Di Natale, C., Cellie, M., Kwok, W., Grandaliano, G., Schena, F.P., Gesualdo, L., & Storkus, W.J. (2002). Identification of HLA-DRB1*0401+-restricted MAGE-6 derived epitopes recognized by Th1/Th2 CD4+T-helper cells in renal cell carcinoma (RCC) patients (PTS). In JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 13, (p. 505A).
Björck, P., Falo, L.D., & Storkus, W.J. (2001). Anti-tumor effect and generation of tumor-specific CD8+ T-cells after combined Flt3L and GM-CSF mobilization and dendritic cell therapy. In FASEB JOURNAL, 15(5), (p. A1200).
Larregina, A.T., Watkins, S.C., Erdos, G., Spencer, L.A., Stolz, D.B., Storkus, W.J., & Falo, L.D. (2001). Direct transfection and activation of human Langerhans cells in situ using biolistic delivery of naked DNA. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 117(4), (p. 1016).
Björck, P., Falo, L.D., & Storkus, W.J. (2000). Generation of CD19+CD11c+ dendritic cells in vivo after combined Flt3L and GM-CSF mobilization. In FASEB JOURNAL, 14(6), (p. A1050).
Björck, P., Falo, L.D., & Storkus, W.J. (2000). Combined Flt3L and GM-CSF mobilization enhance the frequencies of DC subsets exhibiting differential functional capabilities. In FASEB JOURNAL, 14(6), (p. A1132).
Bjorck, P., Lie, W.R., Woulfe, S.L., Klein, B.K., Olson, W., & Storkus, W.J. (2000). Progenipoitin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model. In BLOOD, 96(11), (p. 294A).
Dong, X., An, B., Kierstead, L.S., Warrino, D., Storkus, W.J., Amoscato, A.A., & Salter, R.D. (2000). Extracelluar proteolysis of antigens by CD 13 on dendritic cells. In FASEB JOURNAL, 14(6), (p. A1053).
Le, P.T., Adams, K.L., Mathews, H.L., Zaya, N., Storkus, W.J., & Ellis, T.M. (2000). Human thymic epithelial cells inhibit the development of NK cells. In FASEB JOURNAL, 14(6), (p. A1021).
Mayordomo, J.I., Tres, A., & Storkus, W.J. (2000). Monitoring of CTL responses in cancer patients. In CLINICAL CANCER RESEARCH, 6, (p. 4473S).
Müller-Berghaus, J., Kierstaed, L.S., Ranieri, E., & Storkus, W.J. (2000). IL-12 and human monocyte-derived DC:: Production and phenotype. In FASEB JOURNAL, 14(6), (p. A1050).
Le, P.T., Adams, K.L., Guo, Z., Storkus, W.J., & Ellis, T.M. (1999). Human thymic epithelial cells inhibit the development and expansion of CD3+CD56+TCRαβ+ thymocytes and CD3-CD56+ natural killer cells in vitro. In FASEB JOURNAL, 13(4), (p. A620).
Dong, X., Storkus, W.J., Watkins, S., Stahl, P.D., & Salter, R.D. (1998). Mannose receptor mediated uptake of agalactosyl IgG by dendritic cells: Implication for rheumatoid arthritis. In FASEB JOURNAL, 12(4), (p. A590).
Dong, X., Storkus, W.J., Watkins, S., Stahl, P.D., & Salter, R.D. (1998). Mannose receptor mediated uptake of agalactosyl IgG by dendritic cells: Implication for rheumatoid arthritis. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 70).
Herr, W., Ranieri, E., Gesualdo, L., Zarour, H., & Storkus, W.J. (1998). Detection of CD8+ T lymphocytes responsive to Epstein-Barr virus (EBV) peptide antigens in the blood of healthy EBV carriers. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 74).
Kierstead, L.S., Rice, C., Brusic, V., & Storkus, W.J. (1998). DC facilitate the generation of tumor antigen-specific CD4+ T cells with diverse specificities. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 73).
Marks, M.S., Calvo, P.A., Frank, D.W., Bieler, B., Tuting, T., & Storkus, W.J. (1998). Cytoplasmic signals required for endosomal sorting of tyrosinase. In FASEB JOURNAL, 12(4), (p. A590).
Ranieri, E., Gesualdo, L., Herr, W., Gambotto, A., Logan, T., Zarour, H., Kirkwood, J.M., & Storkus, W.J. (1998). DC-based immunizing strategies to promote anti-renal cancer T cell response. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 74).
Tüting, T., Gambotto, A., DeLeo, A.B., & Storkus, W.J. (1998). Adjuvant administration of plasmid DNA expressing IL-12 enhances the induction of anti-melanoma immune responses with plasmid DNA encoding the murine melanosomal protein TRP-2. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 110(4), (p. 486).
Wilson, C.C., Gambotto, A., Olson, W., Robbins, P., & Storkus, W.J. (1998). Dendritic cells infected with adenovirus-HIV vectors stimulate broad HIV-specific CTL responses. In JOURNAL OF LEUKOCYTE BIOLOGY, (p. 65).
Lotze, M.T., Tahara, H., Storkus, W.J., Suzuki, T., Cai, Q., Couderc, B., & Zitvogel, L. (1997). Cytokine gene therapy of cancer. In CANCER GENE THERAPY, 4(1), (p. 68).
Tuting, T., Baar, J., Schurin, M., Mayordomo, J.I., Zitvogel, L., Tahara, H., Storkus, W.J., DeLeo, A., & Lotze, M.T. (1997). Dendritic cell-based therapy for cancer. In EUROPEAN JOURNAL OF CANCER, 33, (p. 37).
Tuting, T., Kasamon, Y., Martin, D., Wilson, C.C., Baar, J., Lotze, M.T., & Storkus, W.J. (1997). Human blood-derived dendritic cells genetically modified to express melanoma antigens induce primary cytotoxic T cell responses in vitro. In JOURNAL OF INVESTIGATIVE DERMATOLOGY, 108(4), (p. 164).
Tuting, T., Wilson, C.C., Martin, D.I., Baar, J., DeLeo, A., Storkus, W.J., & Lotze, M.T. (1997). DNA vaccines targeting dendritic cells for the immunotherapy of cancer. In CANCER GENE THERAPY, 4(5), (p. 316).
Tüting, T., Zorina, T., Ma, D.I., Wilson, C.C., De Cesare, C.M., De Leo, A.B., Lotze, M.T., & Storkus, W.J. (1997). Development of dendritic cell-based genetic vaccines for cancer. In Adv Exp Med Biol, 417, (pp. 511-518).Springer Nature.United States. doi: 10.1007/978-1-4757-9966-8_84.
Wilson, C.C., Tueting, T., Ma, D., Haluszczak, C., Lotze, M., & Storkus, W. (1997). Activation of dendritic cells by surrogate T cell interactions leads to enhanced costimulation, secretion of TH1-associated cytokines, and CTL inductive capacity. In Adv Exp Med Biol, 417, (pp. 335-343).Springer Nature.United States. doi: 10.1007/978-1-4757-9966-8_55.
Mazzocchi, A., Castelli, C., Traversari, C., Storkus, W.J., Rivoltini, L., Belli, F., Mascheroni, L., Vegetti, C., Anichini, A., & Parmiani, G. (1996). HLA-A3-restricted CTL defined antigens shared among human melanomas but not melanocytes. In FASEB JOURNAL, 10(6), (p. 2520).
MAYORDOMO, J.I., STORKUS, W.J., KAST, W.M., ZORINA, T., DELEO, A.B., & LOTZE, M.T. (1995). BONE-MARROW-DERIVED DENDRITIC CELLS SERVE AS POTENT ADJUVANTS FOR PEPTIDE-BASED ANTITUMOR VACCINES. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 21).
ITOH, T., STORKUS, W.J., GORELIK, E., & LOTZE, M.T. (1993). IDENTIFICATION OF MURINE MELANOMA T-CELL EPITOPES RECOGNIZED BY CD8+ TUMOR INFILTRATING LYMPHOCYTES IN THE CONTEXT OF H-2K(B). In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 138).
LEDER, G.H., STORKUS, W.J., STUBER, G., MODROW, S., & LOTZE, M.T. (1993). P53 PEPTIDES RECONSTITUTE HLA-A2 EXPRESSION AND CONFER SUSCEPTIBILITY TO TIL-LYSIS. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 109).
LOTZE, M.T., RUBIN, J.T., STORKUS, W.J., HURD, S., NASTALA, C.L., EDINGTON, H.E., MCKINNEY, T.G., PIPPIN, B., NISHIHARA, K., TAHARA, H., ELDER, E., WHITESIDE, T., ZIMMERMAN, R., & LOUIE, A. (1993). NEW T-CELL GROWTH-FACTORS IN THE TREATMENT OF CANCER. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 59).
MAEURER, M.J., STORKUS, W.J., SALTER, R.D., & LOTZE, M.T. (1993). MICROPOCKET USAGE IN HLA-A2 PRESENTATION OF MELANOMA PEPTIDES TO CD8+ TUMOR INFILTRATING LYMPHOCYTES (TIL). In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 105).
SALTER, R.D., & STORKUS, W.J. (1993). PEPTIDE RELEASE MUTANTS - IDENTIFICATION OF INFLUENZA-DERIVED PEPTIDES BOUND TO HLA-A2 AND HLA-A69. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 61).
STORKUS, W.J., MAEURER, M.J., ZEH, H.J., & LOTZE, M.T. (1993). IDENTIFICATION OF HUMAN-MELANOMA DERIVED EPITOPES RECOGNIZED BY HLA-A2 RESTRICTED, CD8+ TUMOR INFILTRATING LYMPHOCYTES. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 100).
ZEH, H.J., STORKUS, W.J., BRUNDA, M., GATELY, M., TAHARA, H., & LOTZE, M.T. (1993). IL-12 - A NOVEL-T AND NK STIMULATORY FACTOR - IMPLICATIONS FOR CANCER-IMMUNOTHERAPY. In JOURNAL OF CELLULAR BIOCHEMISTRY, (p. 113).
STORKUS, W., & DAWSON, J.R. (1985). NATURAL-KILLER (NK) CELLS DO NOT GENERATE DETECTABLE OXYGEN METABOLITES AT THE TARGET-CELL INTERFACE. In FEDERATION PROCEEDINGS, 44(4), (p. 1315).